GOLIMUMAB, A NEW HUMAN ANTI-RNF-ALPHA MONOCLONAL ANTIBODY, ADMINISTERED SUBCUTANEOUSLY EVER 4 WEEKS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE:WEEK 24 RESULTS OF THE RANDOMIZED. DOUBLE-BLIND, PLACEBO-CONTROLLED, GO-FORWARD STUDY.